Upper gastrointestinal (GI) endoscopy
ProcedureAn upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.
NCT Number: NCT03596476
Gastro-esophageal reflux disease (GERD) is defined as the reflux of gastric content into the esophagus that causes troublesome symptoms or complications. Nine to 30% of the population suffers from GERD-suggestive symptoms (heartburn, regurgitation, chest pain, chronic couch, sore throat). In the absence of warning signs, proton pump inhibitors (PPI) are prescribed as first-line treatment. However, 20 to 60% of patients are unsatisfied because of persistent symptoms when taking PPI. Causes of persistent symptoms are: erroneous diagnosis of GERD (up to 50% of PPI non-responders), rumination syndrome, excessive weakly acid reflux on PPI due to defective esophago-gastric junction or an excessive number of transient lower esophageal sphincter relaxations (main mechanism of GERD), poor acid secretion inhibition on PPI, and non-compliance to therapy. Complementary examinations are indicated to explain persistent GERD symptoms. Upper gastro-intestinal endoscopy is performed first to rule out an esophageal tumor and to identify erosive esophagitis, a specific sign of GERD. However, it is normal in up to 70% of symptomatic GERD patients. Direct detection of reflux episodes is then requested to confirm GERD. The gold standard for reflux detection is the ambulatory measurement of esophageal pH for 24 to 96 hours using a catheter (catheter-based pH-monitoring) or a capsule clipped into the esophagus (wireless pH-monitoring). Reflux episodes are defined as an esophageal pH < 4. Another method of reflux detection is based on liquid and gas detection in the esophagus using pH-impedance monitoring. Recently the combination of impedance and esophageal pressure monitoring, called esophageal high resolution impedance manometry (HRIM) was introduced to simultaneously identify reflux episodes and their mechanisms. It has several advantages over esophageal pH measurement: shorter recording duration (1 or 2 hours post prandial) and identification of reflux mechanisms that might guide the choice of the best therapeutic option.
Hypothesis: The 1-hour post prandial esophageal HRIM might be useful to diagnose GERD.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Service d'Hepato-Gastroenterologie - Hôpital Trousseau - CHU de Tours, Chambray-lès-Tours, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
An upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.
Wireless pH monitoring will be performed at V1. The pH capsule will be clipped into the esophagus during the upper GI endoscopy. The esophageal pH will be recorded for 96 hours (ambulatory recording).
Post prandial esophageal HRIM will be performed at V2. The recording will be started after transnasal insertion of the HRIM probe. A standardized meal will be given to the patient (Big Mac, medium portion of French fries, orange juice). The recording will be realized for one hour after the end of the meal.
24-h pH-impedance monitoring on PPI will be performed at V3. A transnasal catheter will be inserted into the esophagus and the recording will be performed for 24 hours (ambulatory recording).
Time frame: 1 hour after the end of the meal
The diagnostic performance of the number of reflux episodes measured by 1-hour post prandial HRIM will be evaluated by estimating the Area Under the ROC Curve and its 95% confidence interval. The gold standard to define GERD will be based on esophageal pH measurements with capsule (GERD is defined as acid exposure time (AET; percentage of total time with esophageal pH < 4) greater than 6% for at least one day on wireless pH monitoring).
Time frame: 4 days
The diagnosis of GERD based on pH-monitoring. The diagnosis of GERD is positive if acid exposure time (AET; percentage of total time with esophageal pH < 4) is greater than 6% for at least one day on wireless pH monitoring. The diagnosis of GERD is negative (ie absence of GERD) if the AET is below 4% during the 4 days of wireless monitoring. In the other instance , the diagnosis of GERD is uncertain.
Time frame: 1 hour after the end of the meal
Description of the reflux mechanisms associated with reflux episodes: rumination, transient lower esophageal sphincter relaxation (TLESR), defective esophago-gastric junction (EGJ) or unknown.
Time frame: 1 hour after the end of the meal
Measure of baseline impedance on a period without swallow 3 and 5 cm above the proximal border of the esophago-gastric junction
Time frame: 1 hour
Measure of the resting pressure of the esophago-gastric junction on a period without swallowing
Time frame: 4 weeks
Presence of eosinophils cells in the esophageal mucosa > 15/hpf, dilated intercellular spaces, and/or papillar elongation
Time frame: 4 weeks
Clinical response is defined as a Reflux Disease Questionnaire score on PPI ≤ 3 after 4-week treatment
Time frame: 1 day
The number of reflux episodes is normalized if the total number of reflux episodes is < 60 /24 h) on pH-impedance monitoring performed on PPI.
Time frame: 1 day
The esophageal acid exposure (AET) is normalized if it is below 4% on pH-impedance monitoring performed on PPI.
Time frame: 1 day
Percentage of patients who preferred the wireless pH capsule and percentage of patients who preferred HRIM.
Contact information is provided by the study sponsor or research team.
Hospices Civils de Lyon
Other
Acronym: PRIMER
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03788109
Deglutition Disorders, Digestive System Diseases
Leuven, Vlaams-Brabant, Belgium
View Trial DetailsNCT02456779
Deglutition Disorders, Digestive System Diseases
Beijing, China
View Trial DetailsNCT02114216
Deglutition Disorders, Digestive System Diseases
Seongnam-si, Gyeonggi-do, South Korea
View Trial DetailsNCT01867931
Deglutition Disorders, Digestive System Diseases
Maastricht, Netherlands
View Trial Details